April 24, 2024 News by Andrea Lobo, PhD Foralumab found to ease fatigue in SPMS patients in access program Fully 70% of patients with nonactive secondary progressive multiple sclerosis (SPMS) who received foralumab nasal spray in an expanded access program (EAP) experienced a lessening in fatigue levels after six months of treatment. That’s according to early findings from the EAP ā a program that enables patients with serious…
January 10, 2024 News by Margarida Maia, PhD Foralumab nasal spray shown to ease fatigue in nonactive SPMS Six of eight patients with nonactive secondary progressive multiple sclerosis (SPMS) being treated with foralumab nasal spray ā all part of an intermediate-size expanded access program (EAP) allowing the therapy’s use ā have experienced reductions in their fatigue levels. That’s according to treatment developer Tiziana Life Sciences,…
December 21, 2023 News by Patricia Inacio, PhD Dosing begins in Phase 2a trial of foralumab nasal spray for SPMS Tiziana Life Sciences has dosed the first patient in a Phase 2a clinical trial testing itsĀ foralumab nasal spray in people with nonactive secondary progressive multiple sclerosisĀ (SPMS). The trial will include about 54 participants, enrolled across six clinical sites. Patients will be randomly assigned to receive one of two…
December 4, 2023 News by Andrea Lobo, PhD 4 new SPMS patients dosed with nasal foralumab outside of trials Tiziana Life Sciences has dosed four new participants in an expanded access program investigating its foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS), the company announced. A total of 10 SPMS patients are now being followed outside of clinical trials in foralumab’s expanded…
October 19, 2023 News by Marisa Wexler, MS ECTRIMS 2023: Foralumab seen to ease brain inflammation in SPMS Six months of treatment with foralumab, administered into the nose, led to decreases in microglial activity in five of six people with nonactive secondary progressive multiple sclerosis (SPMS) involved in an expanded access program. Microglia are resident immune cells in the brain believed to play a role in driving…
March 30, 2023 News by Margarida Maia, PhD Tiziana to launch clinical trial for MS therapy foralumab in late 2023 Tiziana Life Sciences plans to launch a Phase 2 clinical trial to investigate its foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS) in late 2023, the company announced. The decision follows a Type C meeting with the U.S. Food and Drug Administration (FDA), wherein…
January 4, 2023 News by Lindsey Shapiro, PhD EDSS Score Drop of 1 Point Seen in 2nd SPMS Patient on Foralumab A second person with non-active secondary progressive multiple sclerosis (SPMS) treated with foralumab nasal spray in a single-patient access program is continuing to show improvements 11 months after starting the therapy, according to an update from foralumab’s developer, Tiziana Life Sciences. The patient, dubbed EA2, experienced a…